EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Analysis of adverse drug reactions in 507 cases of Tislelizumab: A real-world retrospective study based on data from Guangxi, China

Shaohuan Lu, Dajian Chen, Yang Li, Qianxi Chen, Guangyi Meng iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0329464 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Shaohuan Lu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First People's Hospital of Yulin, Yulin, Guangxi, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangxi Science and Technology Major Project, 2022 Pharmaceutical Research Project of Guangxi Pharmaceutical Association Hospital, 2022 Bethune·Quest Pharmaceutical Research Capacity Building Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To analyze the real-world characteristics and patterns of adverse drug reactions (ADRs) associated with tislelizumab, providing valuable insights for clinical practice.

Methods

We conducted a comprehensive analysis of tislelizumab-related ADR reports within the pharmacovigilance system of Guangxi, China, spanning from 01/04/2021–31/08/2024. Our analysis focused on population characteristics, temporal distribution of ADR occurrences, system organ classes (SOCs) of serious adverse drug reactions (SADRs), profiles of major SOCs, and factors influencing SADRs and blood and lymphatic system disorders (BLSDs).

Results

This study analyzed 507 tislelizumab ADR reports (698 events), including 282 SADRs (356 events), with no deaths reported. Pharmacists were the primary reporters (60.55% of reports). Most patients were aged 46–75 years (77.32%), male (72.58%), and of Han ethnicity (75.54%), and 1.78% (9/507) were of Zhuang ethnicity. A total of 86.19% of ADRs occurred within 30 days of medication. Among the SADRs, there were 83 PTs and 17 SOCs, with the most common SOCs being blood and lymphatic system disorders (15.47%, 108/698), investigations (14.90%, 104/698), hepatobiliary disorders (4.15%, 29/698), and skin and subcutaneous tissue disorders (3.15%, 22/698). Logistic regression analysis showed that chemotherapy was a significant risk factor for SADRs (OR = 4.634, 95%CI: 2.871–7.917, P < 0.001). The risk of BLSDs - related ADRs was 5.545 times higher in the chemotherapy-incorporating group than in the monotherapy group (95%CI: 3.423–8.701, P < 0.001).

Conclusions

Close monitoring, particularly in patients receiving chemotherapy-incorporating regimens, is crucial during the first 30 days post-tislelizumab treatment to manage SADR risks. Proactive measures should be implemented if SADR occur.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedDrug-Related Side Effects and Adverse ReactionsHumansMaleFemaleMiddle AgedRetrospective StudiesChinaAgedAdultAdolescentChildYoung AdultChild, PreschoolPharmacovigilanceAged, 80 and overInfantAdverse Drug Reaction Reporting Systems

Substanzen

Antibodies, Monoclonal, Humanizedtislelizumab

Autor:innen und Institutionen

  • Department of Pharmacy, The First People's Hospital of Yulin, Yulin, Guangxi, China.
  • Adverse Drug Reaction Monitoring Office, Yulin Food and Drug Inspection and Testing Center, Yulin, Guangxi, China.

ORCID-Profile: Guangyi Meng

Förderung

  • Guangxi Science and Technology Major Project
  • 2022 Pharmaceutical Research Project of Guangxi Pharmaceutical Association Hospital
  • 2022 Bethune·Quest Pharmaceutical Research Capacity Building Project

Zitieren

APA

Lu, S., Chen, D., Li, Y., Chen, Q., & Meng, G. (2025). Analysis of adverse drug reactions in 507 cases of Tislelizumab: A real-world retrospective study based on data from Guangxi, China. PLOS One. https://doi.org/10.1371/journal.pone.0329464

Vancouver

Lu S, Chen D, Li Y, Chen Q, Meng G. Analysis of adverse drug reactions in 507 cases of Tislelizumab: A real-world retrospective study based on data from Guangxi, China. PLOS One. 2025. doi:10.1371/journal.pone.0329464

BibTeX
@article{Lu2025,
  author = {Lu, Shaohuan and Chen, Dajian and Li, Yang and Chen, Qianxi and Meng, Guangyi},
  title = {Analysis of adverse drug reactions in 507 cases of Tislelizumab: A real-world retrospective study based on data from Guangxi, China},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0329464}
}
Kostenlos starten →